5-Quinolinesulfonic acid, 8-hydroxy-7-(6-sulfo-2-naphthylazo)- manufacturers
- NSC-87877
-
- $30.00
-
2026-07-31
- CAS:56990-57-9
- Purity: 97.35%
- Supply Ability: 10g
|
| | 5-Quinolinesulfonic acid, 8-hydroxy-7-(6-sulfo-2-naphthylazo)- Basic information |
| | 5-Quinolinesulfonic acid, 8-hydroxy-7-(6-sulfo-2-naphthylazo)- Chemical Properties |
| density | 1.697±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | Store at +4°C | | solubility | ≥45.9 mg/mL in DMSO; insoluble in EtOH; ≥16.6 mg/mL in H2O with ultrasonic | | form | Powder | | pka | -0.119±0.40(predicted) | | color | Light brown to black |
| | 5-Quinolinesulfonic acid, 8-hydroxy-7-(6-sulfo-2-naphthylazo)- Usage And Synthesis |
| Uses | NSC 87877 is an inhibitor of SHP2 and SHP1 protein tyrosine phosphatases | | Definition | ChEBI: 8-oxo-7-[(6-sulfo-2-naphthalenyl)hydrazinylidene]-5-quinolinesulfonic acid is a naphthalenesulfonic acid. | | Biological Activity | Potent inhibitor of shp2 and shp1 protein tyrosine phosphatases (PTP) (IC 50 values are 0.318, 0.355, 1.691, 7.745, 65.617, 84.473 and 150.930 μ M for shp2, shp1, PTP1B, HePTP, DEP1, CD45 and LAR respectively). Inhibits EGF-induced Erk1/2 activation in HEK293 cells and significantly reduces MDA-MB-468 cell viability/proliferation. | | in vivo | NSC-87877 (30mg/kg, IP once daily for 15 days) possesses excellent anti- neuroblastoma activity[3].
| Animal Model: | Intrarenal neuroblastoma (NB) tumor mouse model in female nude mice[3].
| | Dosage: | 30mg/kg. | | Administration: | IP once daily for 15 days. | | Result: | Significantly inhibited NB tumor growth. |
| | storage | Store at +4°C |
| | 5-Quinolinesulfonic acid, 8-hydroxy-7-(6-sulfo-2-naphthylazo)- Preparation Products And Raw materials |
|